On August 20, the bidding results of the third-batch national centralized drug procurement were announced. Five drugs of Jiangsu Hansoh Pharmaceutical Group Co., Ltd. ("Hansoh Pharma") stood out and won the bid, namely, Hengjie (Linezolid Tablets), Hengdan (Cefdinir Capsules), Fulaile (Vigliptin Tablets), Ruiyisheng (Prucalopride Succinate Tablets) and Zexin (Apixaban Tablets). The bid winning of the above five drugs is a strong testimony of Hansoh Pharma's R&D innovation, product quality and enterprise strength. Since the state started centralized drug procurement, Hansoh Pharma has responded positively to the national policy call to take concrete actions to significantly reduce the economic burden of medication and improve the accessibility of medication for patients.

Hengjie (Linezolid Tablets)

Linezolid is a severe anti-infective drug unanimously recommended by clinical guidelines of various countries. It is recommended as the first choice drug in Group A for long-term treatment of multidrug-resistant tuberculosis by the World Health Organization (WHO) in the 2019 List of Essential Medicines, bringing a new option to drug-resistant tuberculosis patients. In December 2019, Hansoh Pharma's Linezolid Tablets were approved for marketing, which allows easier long-term use by patients, improves medication accessibility and reduces medication burden.

Hengdan (Cefdinir Capsules)

Cefdinir developed by Hansoh Pharma is the third-generation oral cephalosporin, characterized by broad antibacterial spectrum, high efficacy and low toxicity. The drug was approved for marketing in China in 2008. It was the first in China to pass the generic drug consistency evaluation in 2019, and was successively recognized as a high-tech product in Jiangsu Province and a national key new product.

Fulaile (Vildagliptin Tablets)

In March 2019, Hansoh Pharma's first generic of Fulaile was approved by the State Drug Administration, primarily for the treatment of type II diabetes, and its approval also means that Fulaile is deemed to have passed the consistency evaluation. Vildagliptin has a unique hypoglycemic mechanism to promote insulin release and glucagon secretion, and the approval of the first generic of Fulaile provides Hansoh Pharma's diabetes product line with another new "silver bullet" for clinical treatment of type II diabetes. 

Ruiyisheng (Prucalopride Succinate Tablets)

The approval of Ruiyisheng, an oral gastrointestinal motility promoting drug, in December 2018 has enriched and diversified the gastrointestinal product line structure of Hansoh Pharma, bringing safe and effective treatment to the vast number of chronic constipation patients in China, and meeting the long-standing expectation of patients for fundamental treatment of chronic constipation.

Zexin (Apixaban Tablets)

Zexin, the first domestic generic anticoagulant from Hansoh Pharma, was approved in January 2019. Zexin is a new oral anticoagulant for the prevention of venous thromboembolism (VTE) in adult patients undergoing hip or knee arthroplasty. It provides a new option for anticoagulation therapy after clinical orthopedic surgery, improves medication availability for patients, and enables more domestic patients undergoing elective hip/knee arthroplasty in China to benefit.

It's reported that a total of 189 enterprises participated in the procurement, involving more than 300 product specifications, and finally 55 varieties were successfully procured. The number of drug varieties was close to the sum of the first two batches, drawing much attention from the industry. The bid winning of five drugs from Hansoh Pharma will benefit more patients and bring positive social benefits.

In the future, Hansoh Pharma will make further efforts to live up to its corporate mission to "create excellence in pharmaceuticals, enhance innovation in China", accelerate scientific and technological innovation, and continuously improve product quality and medication accessibility, so as to bring more high-quality and affordable drugs to domestic patients.